Carbasalate Calcium Application for Hydrocephalus Treatment
Summary
The USPTO published patent application US20260091044A1 by Tianjin University covering the use of carbasalate calcium as the sole or primary active ingredient for treating hydrocephalus. The application includes zebrafish model experimental data demonstrating significant reduction in fourth ventricle area and improvements in swimming metrics. No regulatory compliance deadlines or penalties apply to this patent application publication.
What changed
Tianjin University filed patent application US20260091044A1 with the USPTO on February 21, 2025 (published April 2, 2026) for the application of carbasalate calcium in preparing drugs for hydrocephalus treatment. The invention reports that carbasalate calcium significantly reduced fourth ventricle area in zebrafish hydrocephalus models and improved swimming distance, time, speed, and rotational motion frequency. The application lists 11 inventors and claims the drug uses carbasalate calcium as the only or main active ingredient.
This is a patent application publication with no immediate regulatory compliance requirements. Pharmaceutical companies developing neurological treatments, researchers studying hydrocephalus therapies, and patent practitioners should monitor this application through the examination process. No deadlines, filing requirements, or penalties are associated with this publication. The application represents early-stage research findings that may influence future drug development for hydrocephalus if the patent is granted and the treatment advances to clinical trials.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
APPLICATION OF CARBASALATE CALCIUM IN PREPARING DRUG FOR TREATMENT OF HYDROCEPHALUS
Application US20260091044A1 Kind: A1 Apr 02, 2026
Assignee
Tianjin University
Inventors
Dong MING, Xiuyun LIU, Meijun PANG, Hui ZHI, Xiaosong GU, Xiaoguang TONG, Huijie YU, Wenyuan GAO, Ke PU, Zongwei CAI, Weijian ZONG
Abstract
An application of carbasalate calcium in preparing the drug for the treatment of hydrocephalus is provided, and the drug uses carbasalate calcium as the only or main active ingredient. The invention first discovered the effect of carbasalate calcium in the treatment of hydrocephalus, which can significantly reduce the area of the fourth ventricle of the zebrafish model of hydrocephalus, and significantly increase the swimming distance, swimming time, swimming speed, and rotational motion frequency of the zebrafish model of hydrocephalus; the experimental data provided by the invention show that carbasalate calcium has great application prospects in the treatment of hydrocephalus, and provides an effective candidate drug for alleviating the pain of hydrocephalus patients and reducing the risk and cost of treatment; it broadens the scope of action of carbasalate calcium.
CPC Classifications
A61K 31/616 A61K 31/17
Filing Date
2025-02-21
Application No.
19059317
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.